MIF and metastatic melanoma: Blocking MIF signaling through CD74 on MOs and DCs, using the C36L1 Ig-CDR-based peptide, restores the pro-inflammatory functions of MOs and DCs thereby harnessing the immune response against metastatic melanoma.